FDA Approves Lenvatinib and Pembrolizumab Combination for Advanced Renal Cell Carcinoma

The FDA has granted approval to the combination of lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for the treatment of patients with advanced renal cell carcinoma (RCC) who are undergoing first-line treatment. "Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced RCC," wrote Robert Motzer, MD, Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center, and colleagues, in their publication of results of the p...
Continue reading

Exploring Treatment Options for Patients With Renal Cell Carcinoma: Bradley McGregor, MD, and Robert Motzer, MD

In 2021, an estimated 76,080 new cases of kidney cancer will be diagnosed. Among those cases, the majority will be renal cell carcinomas (RCC). In this excerpt of the transcript from their continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Expert Guidance on New Advances in Renal Cell Carcinoma, Bradley McGregor, MD, Clinical Director of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, and Robert Motzer, MD, Chair ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.